TB drug discovery
What is it about?
This is our broad perspective on tuberculosis drug discovery using examples of obtained through our EU-funded FP7 collaborations, New Medicines for Tuberculosis was target-based and our more-recent More Medicines for Tuberculosis project. We describe success and failure with target-based and phenotypic screening
Why is it important?
We provide brief reviews on the work done on DprE1 and PimA as well as discussion of computational approaches that can be used to predict in vivo activity. Our discussion points to the complexity in understanding the drug targets and the complex effects of the drugs on Mycobacterium tuberculosis. We suggest that we should be doing more to leard from our prior data whether from this collaboration or elsewhere.
The following have contributed to this page: Dr Sean Ekins